一、2024 年度监事会工作情况 （一）报告期内，监事会共召开 5 次会议，具体情况如下: 1、2024 年 1 月 31 日，公司第七届监事会第十五次会议审议通过了《关于 为全资子公司向银行申请授信额度提供担保的议案》。 2、2024 年 4 月 26 日，公司第七届监事会第十六次会议审议通过了《关于 2023 年度监事会工作报告的议案》《关于公司 2023 年度财务决算报告的议案》 《关于公司 2023 年度利润分配预案的议案》《关于公司 2023 年年度报告及摘要 的议案》《关于公司 2023 年度内部控制评价报告的议案》《关于公司 2023 年度 募集资金存放与使用情况专项报告的议案》《关于 2023 年度计提资产减值准备 的议案》《关于<未来三年（2024 年-2026 年）股东回报规划>的议案》《关于公 司 2024 年第一季度报告的议案》《关于公司及全资子公司向银行申请授信额度 及担保事项的议案》《关于使用闲置募集资金进行现金管理的议案》《关于公司 及全资子公司使用自有资金购买理财产品的议案》。 3、2024 年 8 月 28 日，公司第七届监事会第十七次会议审议通过了《关于 公司 2024 年 ...

深圳康泰生物制品股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的专项说明 | 索引 | 页码 | | --- | --- | | 非经营性资金占用及其他关联资金往来的专项说明 | 1 | | 附件一 | 1 | 关于深圳康泰生物制品股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025SZAA4B0186 深圳康泰生物制品股份有限公司 深圳康泰生物制品股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了深圳康泰生物制品股份有限公司（以下简称康 泰生物）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表、2024 年 度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表以及财 务报表附注，并于 2025 年4 月18 日出具了 XYZH/2025SZAA4B0209 无保留意见的审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往来、对外 担保的监管要求》 （证监会公告[2022]26 号），以及深圳证券交易所相关披露的要求，康泰 生物编制了本专项说明所附的康 ...

深圳康泰生物制品股份有限公司 关于公司及全资子公司使用自有资金购买理财产品的公告 | 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、投资品种：安全性高、流动性好、风险可控的理财产品。 2、投资金额：本次公司及全资子公司以自有资金购买理财产品的最高额度 不超过 400,000.00 万元，额度使用期限为自本次董事会审议通过之日起至下一 年度董事会重新审议该事项之日止，在上述额度和期限范围内可循环滚动使用。 3、特别风险提示：公司拟投资的理财产品属于安全性高、流动性好、风险 可控的理财产品，但金融市场受诸多因素的影响，不排除投资收益因市场波动的 影响，存在一定的风险。 深圳康泰生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开第八届董事会审计委员会 2025 年第二次会议、第八届董事会第五次会议 和第八届监事会第二次会议，会议审议通 ...

| 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召 开第八届董事会第五次会议，会议审议通过了《关于召开 2024 年度股东大会的议 案》，现将本次股东大会会议相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、召集人：公司董事会。经公司第八届董事会第五次会议审议通过后，决定 召开 2024 年度股东大会。召集程序符合法律、法规、规范性文件和公司章程的规 定。 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《深圳证 券交易所创业板股票上市规则》等有关法律、法规、部门规章、规范性文件及《公 司章程》《股东大会议事规则》的规定。 4、 ...

债券代码：123119 债券简称：康泰转 2 证券代码：300601 证券简称：康泰生物 公告编号：2025-035 深圳康泰生物制品股份有限公司 第八届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）第八届监事会第二次 会议通知于2025年4月8日以书面及通讯方式通知了全体监事，会议于2025年4月 18日在公司会议室以现场表决和通讯表决相结合的方式召开。会议由监事会主席 温飞东先生召集并主持。本次会议应参加表决监事3名，实际参加表决监事3名。 公司部分高级管理人员列席本次会议。本次会议的召集、召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的有关规定。 经过全体监事认真审议，会议通过了相关议案并形成如下决议： 一、审议通过了《关于2024年度监事会工作报告的议案》，表决结果：3票 同意，0票反对，0票弃权。 《2024年度监事会工作报告》的具体内容详见公司同日在巨潮资讯网 （http://www.cninfo.com.cn）披露的公告。 本议案尚需提交公司 2024 ...

| 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2025-034 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）第八届董事会第五次 会议通知于 2025 年 4 月 8 日以书面及通讯的方式通知了全体董事，会议于 2025 年 4 月 18 日在公司会议室以现场表决和通讯表决相结合的方式召开。会议召集 人及主持人为公司董事长杜伟民先生，本次会议应参加表决董事 7 人，实际参加 表决董事 7 人。公司监事、高级管理人员列席本次会议。会议的召集召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 经过全体董事认真审议，会议通过了相关议案并形成如下决议： 一、审议通过了《关于 2024 年度总裁工作报告的议案》，表决结果：7 票同 意、0 票反对、0 票弃权。 二、审议通过了《关于 2024 年度董事会工作报告的议案》，表决结果：7 票 同意、0 票反对、0 票弃权。 《20 ...

债券代码：123119 债券简称：康泰转 2 证券代码：300601 证券简称：康泰生物 公告编号：2025-036 深圳康泰生物制品股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 深圳康泰生物制品股份有限公司（以下简称"公司"）于2025年4月18日召 开第八届董事会审计委员会2025年第二次会议、第八届董事会第五次会议、第八 届监事会第二次会议，分别审议通过了《关于2024年度利润分配预案的议案》， 本议案尚需提交公司2024年度股东大会审议。 （一）董事会审计委员会意见 2025年4月18日，公司召开第八届董事会审计委员会2025年第二次会议，以3 票同意、0票反对、0票弃权的表决结果审议通过了《关于2024年度利润分配预案 的议案》。董事会审计委员会认为本次利润分配预案，符合公司整体发展战略和 实际经营情况，有利于全体股东共享公司的经营成果。该利润分配预案符合公司 的利润分配政策，符合《公司法》《证券法》《上市公司监管指引第3号—上市 公司现金分红》等相关法律法规以及《公司章程》的相关 ...

前十大流通股东累计持有： 36182.99万股，累计占流通股比： 41.07%，较上期变化： 32.99万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1800 | 0.7700 | -76.62 | -0.1200 | | 每股净资产（元） | 0 | 8.09 | -100 | 7.56 | | 每股公积金(元) | 4.93 | 4.81 | 2.49 | 4.9 | | 每股未分配利润(元) | 1.95 | 1.98 | -1.52 | 1.46 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 26.52 | 34.77 | -23.73 | 31.57 | | 净利润(亿元) | 2.02 | 8.61 | -76.54 | -1.33 | | 净资产收益率(%) | 2.11 | 9.26 | -77.21 | -1.44 | 数据四舍五入，查看更多财务数据>> 二 ...

Financial Performance - The company's operating revenue decreased compared to the previous year due to market competition and inventory reduction [4]. - The net profit for 2024 declined compared to the previous year, influenced by increased fixed asset depreciation and asset impairment [4]. - The company's revenue for 2024 was approximately ¥2.65 billion, a decrease of 23.75% compared to ¥3.48 billion in 2023 [19]. - Net profit attributable to shareholders for 2024 was approximately ¥201.65 million, down 76.59% from ¥861.30 million in 2023 [19]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately ¥245.99 million, a decline of 65.93% from ¥722.05 million in 2023 [19]. - The net cash flow from operating activities for 2024 was approximately ¥603.25 million, a decrease of 41.61% compared to ¥1.03 billion in 2023 [19]. - Basic earnings per share for 2024 were ¥0.18, down 76.62% from ¥0.77 in 2023 [19]. - Total assets at the end of 2024 were approximately ¥14.56 billion, a decrease of 3.46% from ¥15.09 billion at the end of 2023 [19]. - Net assets attributable to shareholders at the end of 2024 were approximately ¥9.66 billion, an increase of 1.25% from ¥9.54 billion at the end of 2023 [19]. - The company reported a weighted average return on equity of 2.11% for 2024, down 7.15% from 9.26% in 2023 [19]. - The company experienced a net loss in the fourth quarter of 2024, with a net profit of -¥149.44 million [21]. - The total impact of non-recurring gains and losses for the company was reported at -$44,336,541.42, compared to $139,252,036.31 in 2023 [25]. - The company reported a significant increase in other business income, which rose by 301.17% to approximately ¥44.76 million in 2024 [69]. - The company reported a net cash increase of -¥754,256,544.65, a decline of 528.03% year-on-year [86]. - The company’s total liabilities increased, impacting its financial stability, with significant asset impairment losses reported [88]. Dividend and Profit Distribution - The profit distribution plan proposes a cash dividend of 0.9 yuan per 10 shares (tax included) for all shareholders [5]. - A profit distribution plan for 2024 proposes a cash dividend of 0.90 yuan per 10 shares, totaling approximately 100.52 million yuan, which represents 49.85% of the net profit attributable to shareholders [136]. - Since its listing in 2017, the company has distributed a total of 1.885 billion yuan in cash dividends, accounting for 45.06% of the total net profit attributable to shareholders [136]. - The total cash dividend amount is approximately 100.52 million CNY, which represents 100% of the total profit distribution amount [191]. Market and Industry Trends - In 2023, the global vaccine market size reached approximately 7 billion doses, with a financial value of about $77 billion, accounting for 5% of the total global pharmaceutical market revenue [27]. - The compound annual growth rate (CAGR) of the global vaccine market from 2019 to 2023 was 15%, with projections estimating it will reach approximately $83.1 billion by 2025 and $131 billion by 2030 [27]. - The adult vaccine market is expected to grow significantly, driven by an increasing elderly population, which is projected to reach 22% of the population aged 60 and above in 2024 [31]. - The demand for innovative vaccines and multi-valent vaccines is expected to rise, with advancements in AI and biotechnology paving the way for new vaccine technologies [32]. - The Chinese vaccine industry is undergoing structural adjustments and technological upgrades, with opportunities for market consolidation among leading companies [28]. - The company anticipates that the implementation of various national policies will further promote the regulatory standardization and innovative upgrades within the vaccine industry [30]. - The global vaccine market presents significant opportunities, with 68 countries reporting national-level vaccine shortages in 2023, highlighting the demand for vaccines [34]. Research and Development - The company has developed a strong R&D capability in human vaccines, with over 30 years of experience, and has a diverse product portfolio including viral, bacterial, and genetic engineering vaccines [36]. - The company has 13 approved vaccines, including the 13-valent pneumococcal conjugate vaccine and the recombinant hepatitis B vaccine, covering 31 provinces in China [36]. - R&D investment for 2024 is 569 million yuan, accounting for 21.47% of annual revenue, with cumulative R&D investment over the past three years reaching 2.11 billion yuan, or 22.67% of cumulative revenue [46]. - The company is focusing on innovative vaccine technologies, including mRNA and viral vector technologies, and has signed a strategic cooperation agreement with AstraZeneca to establish a joint venture in Beijing [48]. - The company has nearly 30 projects in the research pipeline, with several entering the registration process, including vaccines for polio, influenza, and hepatitis A [55]. - The company has established a comprehensive product pipeline targeting adult immunization needs, including vaccines for RSV and shingles, leveraging new technologies such as mRNA [61]. - The company has a dedicated team for mRNA and new adjuvant research, focusing on developing vaccines for RSV and shingles [61]. - The company has completed phase III clinical trials for several vaccines, including the ACYW135 meningococcal vaccine and the inactivated hepatitis A vaccine, which are now in the final stages of registration [55]. International Expansion - The company is accelerating its internationalization strategy, with multiple domestic vaccines receiving WHO pre-certification, enhancing global accessibility and affordability [33]. - The international market strategy includes local partnerships for product registration and distribution, adapting to regulatory requirements in target countries [43]. - The company is actively pursuing international expansion, having established partnerships in over ten countries and covering regions such as Southeast Asia, the Middle East, and Eastern Europe [64]. - The first batch of the "dual-vector" 13-valent pneumococcal polysaccharide conjugate vaccine was successfully exported to Indonesia in August 2024 [49]. Risk Management - The company emphasizes that future development plans do not constitute a substantive commitment to investors, highlighting investment risks [4]. - The management discussion section outlines potential operational risks and corresponding countermeasures [4]. - The company faces risks from industry policy changes and will adapt strategies to mitigate potential impacts [121]. - There are concerns regarding new product development not meeting expectations, with a focus on quality and risk management [122]. - The company will strengthen its adverse event management system to minimize risks associated with vaccine administration [124]. Governance and Management - The company has updated its internal control systems and governance structure, enhancing compliance training and risk management practices [52]. - The company has a board of directors consisting of 7 members, including 3 independent directors, and held 9 board meetings during the reporting period [143]. - The company emphasizes the protection of stakeholders' rights, including shareholders, employees, customers, and suppliers, promoting sustainable development [148]. - The company operates independently from its controlling shareholder in terms of business, assets, personnel, and finance, with no related party transactions or competition [150][151][152][154]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, aiming to enhance motivation and retain talent [147]. - The company has maintained a stable shareholding structure among its top executives, indicating confidence in its strategic direction [160]. Employee Development - The total number of employees at the end of the reporting period is 1,913, with 581 in the parent company and 1,332 in major subsidiaries [186]. - The company emphasizes a compensation policy that links employee pay to performance, aiming to enhance human resource competitiveness [187]. - The company has implemented a salary performance system based on job value and individual capability, aligning employee income with business performance [187]. - The company emphasizes continuous employee training and development to enhance professional skills and business capabilities [188]. - The company advocates for lifelong learning among employees to meet the evolving demands of the business environment [188]. Strategic Initiatives - The company aims to enhance its vaccine product matrix by focusing on adult vaccine projects and optimizing existing products [115]. - Plans to accelerate international market expansion, targeting Southeast Asia, South Asia, the Middle East, Africa, and Latin America [116]. - The company is committed to deepening its core business, enhancing R&D innovation, and accelerating globalization to improve international market competitiveness [136]. - The company has implemented a "Quality and Return Dual Improvement" action plan to enhance investor confidence and market stability [135].

Financial Performance - The company's revenue for Q1 2025 was CNY 645,202,778.57, representing a 42.85% increase compared to CNY 451,659,438.75 in the same period last year[3] - Net profit attributable to shareholders decreased by 58.51% to CNY 22,434,088.56 from CNY 54,065,937.45 year-on-year[3] - The basic earnings per share decreased by 60.00% to CNY 0.02 from CNY 0.05 in the same period last year[3] - Net profit for the current period was ¥22,385,110.07, a decrease of 59% from ¥54,028,967.57 in the previous period[22] - The total comprehensive income for the current period was ¥22,328,228.76, down from ¥54,028,967.57, indicating a decrease of approximately 59%[23] Cash Flow - The net cash flow from operating activities improved by 39.22%, reaching CNY -46,303,417.98, compared to CNY -76,178,859.85 in the previous year[8] - Cash inflow from operating activities was ¥581,746,831.93, compared to ¥551,108,624.59 in the previous period, showing an increase of approximately 5.6%[25] - The net cash flow from investment activities was -65,225,875.91, compared to -377,609,311.64 previously[26] - Cash inflow from financing activities was 25,584,357.78, a decrease from 146,913,282.57 in the last period[26] - The net cash flow from financing activities was -98,941,780.52, contrasting with a positive 122,766,816.17 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 14,254,927,648.54, a decrease of 2.12% from CNY 14,563,714,495.33 at the end of the previous year[3] - The company reported a total liability of ¥4,571,533,462.31, down from ¥4,902,689,146.32 in the previous period, indicating a reduction of approximately 7%[21] - The company has a total of 8,025,395,103.09 in non-current assets, down from 8,321,425,556.94 at the beginning of the period, indicating a decrease of approximately 3.6%[18] - The company’s total liabilities and equity amounted to ¥14,254,927,648.54, a decrease from ¥14,563,714,495.33 in the previous period, representing a reduction of about 2.1%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 62,638[10] - The company reported a total of 231,096,718 shares under lock-up restrictions, with 154,050 shares newly added during the period[14] - The company has a total of 10 major shareholders, with the largest shareholder holding 201,730,680 shares, accounting for a significant portion of the total shares[11] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[12] Operating Costs and Expenses - The company reported a significant increase in operating costs, which rose by 137.99% to CNY 171,263,111.04, primarily due to increased sales volume[7] - Total operating costs amounted to ¥594,453,971.64, up 41% from ¥420,220,371.94 in the prior period[21] - Research and development expenses rose to ¥120,628,293.10, up from ¥107,609,673.57, marking a growth of about 12%[22] Other Financial Metrics - The company’s weighted average return on equity decreased to 0.23% from 0.56% year-on-year[3] - The company’s cash and cash equivalents decreased significantly from CNY 432,840,378.47 to CNY 219,937,690.38, representing a decline of about 49.3%[17] - Accounts receivable increased from CNY 2,787,045,936.42 to CNY 2,854,264,706.31, indicating a growth of approximately 2.4%[17] - Inventory decreased from CNY 782,767,957.21 to CNY 726,163,704.93, a reduction of about 7.2%[18] - Total current liabilities decreased from CNY 2,300,000,000 to CNY 2,200,000,000, reflecting a decrease of approximately 4.3%[17] Compliance and Regulations - The company disclosed that all major events as per the Securities Law and the Management Measures for Information Disclosure of Listed Companies have been reported in compliance with regulations[15] - The company did not undergo an audit for the first quarter report[27] - The new accounting standards will be implemented starting in 2025, but the company is not applicable for the current adjustments[28]